10FDA approval & the 1988 NIH consensus
A device can work and still not be accepted. For the cochlear implant, the transition from contested experiment to standard therapy was made not only in laboratories and operating theatres but in regulatory offices and consensus panels. The FDA's approvals — single-channel in 1984, multichannel in 1985, and, decisively, children in 1990 — opened the device to routine clinical use. The NIH consensus conferences put the weight of the scientific establishment behind it, declaring implantation an effective and appropriate treatment. This module is about that quieter, institutional half of the story, without which the engineering triumph would have stayed in the clinic of a few enthusiasts.
FCrossing the threshold of legitimacy
Through the 1970s the cochlear implant was, to much of the profession, an unproven and even reckless venture. What changed that perception was a sequence of institutional validations: regulatory approval, which made the device a lawful, reimbursable treatment, and consensus endorsement, which made recommending it respectable. These were not mere formalities; they were the mechanisms by which a fringe technology became mainstream medicine.
FTThe FDA approvals
In 1984 the FDA approved the House/3M single-channelimplant for adults — the first cochlear implant cleared for market, vindicating House's long persistence (Module 4). Just a year later, in 1985, it approved the multichannel Nucleus 22for adults (Module 7). The speed of that second approval, and the multichannel device's superior speech results, meant the market moved decisively toward multichannel implants almost as soon as they were available.
CThe pivotal step — children
The most consequential approval came in 1990, when the FDA cleared multichannel implantation in children (initially down to age two). This was the step that connected the implant to the science of brain development: a deaf child implanted early can receive organised auditory input while the sensitive period for central auditory and language development is still open (Chapter 3). Paediatric approval transformed the implant from a device that restored lost hearing in adults into one that could build hearing in children who had never had it.
Implanting children was, at the time, ethically and culturally charged — opposed by some who questioned consenting on a child's behalf and by parts of the Deaf community who did not regard deafness as a deficit to be corrected. The decision to approve paediatric implantation, and to push the age ever lower, was made on the developmental evidence that earlier is better — a tension the atlas treats with care elsewhere.
CThe NIH consensus
Scientific legitimacy was conferred by the NIH Consensus Development process. The first conference, in 1988, reviewed the evidence and endorsed cochlear implantation; a second statement in 1995 went further, affirming its effectiveness in both adults and children and noting that many recipients could understand speech without lip-reading. Coming from a neutral, authoritative panel, these statements moved the implant firmly into accepted practice and shaped reimbursement and referral for years.[1995]
FWhat acceptance changed
With approval and consensus in hand, the cochlear implant stopped being a question of whether and became a question of how best— which devices, which candidates, which age, one ear or two. The history's final movement is that widening: once the implant was legitimate, its indications expanded steadily outward (Module 11).
Which approval connected the implant most directly to brain development?
Which FDA milestone was most significant for the developing brain?
What role did the NIH consensus statements play?